ABSI heads into the final days of June with a jarring contradiction: the stock fell nearly 12% on Tuesday while the Street is busily raising price targets to levels well above the current price.
The analyst tone has shifted decisively upward in recent weeks. BTIG raised its target to $13 on June 24 — the same day the stock was selling off — after initiating at $9 just weeks earlier. Guggenheim lifted its target to $15 from $10 on June 15. Leerink Partners started coverage with an Outperform and a $12 target on June 4. Every recent action has been a raise or a fresh Buy/Outperform initiation. The consensus mean target of $9.61 was set before these latest moves and is already stale; the working range now sits between $12 and $15 across the most recent contributors. Against a close of $7.41, that represents a wide valuation gap — though closing it depends entirely on clinical execution. The analyst recommendation differential factor scores in the 98th percentile relative to the broader universe, reflecting just how one-sided the Street has become on the name.
The short side tells an equally striking story, and it points in the opposite direction. At 20.5% of the free float, short interest is substantial — roughly one share in five is borrowed and sold short. That level has been remarkably stable, barely moving over the past month (down just 1.3%). Short sellers are not covering despite a stock that has gained 45% in a month and 6% on the week before Tuesday's slide. Borrow conditions explain why they are comfortable holding: cost to borrow is just 0.74%, near its lowest level of the past 30 days, and availability has actually loosened sharply — from around 65% a month ago to 106% now. More shares are available to lend than are currently borrowed, meaning new shorts face no friction entering the trade. The ORTEX short score of 73.8 places ABSI well above average on bearish positioning signals, ranking in just the 8th percentile for short score rank — a sign the data flags this as one of the more heavily shorted names in the universe.
Options traders are not particularly alarmed. The put/call ratio of 0.075 sits near the low end of its 52-week range, barely above a standard deviation from its 20-day mean. That's a call-heavy skew, consistent with speculative long interest rather than hedging pressure — and it stands in contrast to the high short interest. The two signals are genuinely divergent: options buyers are positioned for upside, short sellers remain dug in.
The ownership structure adds another layer. ARK Investment Management added 1.17 million shares through May, bringing its stake to 8.8% of shares. State Street added 1.33 million shares in the same period. Founder and CEO Sean McClain holds 5.7% directly. On the insider side, Director Menelas Pangalos bought roughly $200,000 worth of stock in May at $5.36 — a price now well below where the stock trades. The 90-day net insider position is a modest positive at $655,000 net bought, driven by those director purchases against routine executive sells. The buy side of the register is growing; the sell side looks like tax-driven vesting rather than conviction selling.
The next earnings date is August 7. The most recent print on June 4 produced a one-day gain of 7.7% and a five-week gain of nearly 10%, a notable departure from the May 7 result which saw a flat open followed by a 6.9% five-day decline. With the stock up 45% in a month and a dense cluster of fresh analyst initiations providing narrative support, the August print becomes a test of whether the AI-driven drug discovery platform can back the momentum with operational progress — and whether 20% short interest at rock-bottom borrow cost finally starts to move.
See the live data behind this article on ORTEX.
Open ABSI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
